Currently, the majority of clinical trial sites in the United States use paper cheques as their primary method of payment. Samuel Whitaker, Co-Founder & Chief Executive Officer at Greenphire, overviews the conventional subject payment process, identifies its shortcomings, and discusses how new electronic payment solutions are set to revolutionise subject payment in clinical trials.
Large molecule drugs are complex, biologically synthesised pharmaceutical compounds. Owing to their complexity, large molecule drugs, such as proteins and antibodies, can be efficiently analysed using indirect immunochemical/ligand binding techniques. However, these techniques are time-consuming, creating an additional burden for bioanalytical applications. Chris Beaver, Director of Immunochemistry Services at PharmaNet, summarises the challenges of managing commercially available research grade kits during clinical trials and outsourcing to contract research organisations.
With many thousands of experienced investigators globally, and innumerable completed studies, why do we need to be particularly concerned with assessing the feasibility of a clinical trial? Dr Guy Patrick MD PhD, Chief Executive Officer and Chief Medical Officer of Centrical Global Clinical Trials, explores significant pressures that have been building within the clinical trials industry to drive greater cost efficiencies and to ensure delivery of complete and quality data on time and on budget.
Twenty years ago, research sites alone would provide their total enrolment quota simply by reaching into their own database of patients. But in the last two decades, the clinical trial landscape has changed and the ripple effect has meant that sites need to go outside their practice for patients. Scott Connor, Vice President of Marketing, and Joe O’Rourke, Manager of Customer Solutions, at Acurian, consider the reasons why additive patient recruitment is no longer a nice-to-have or a rescue solution.
The essential background of technology is being masterminded by specialists in the exacting science of cryogenics. Patrick Jackson, a qualified engineer at Vindon Scientific, explores how technology is often reliant on the expertise of one or more partners joining forces to improve overall resources.
Maria Toloudi, Marina Chatziioannou and Loannis Papasotiriou, of Research Genetic Cancer Centre Ltd, investigate the efficacy of Anvirzel™, an extract of Nerium oleander, in more than 35 different human cancer cell lines, including all types of tumours, and how the drug has a wider field of action in other cancer cell lines.